Qiagen Stock Price, News & Analysis

QIAGEN has launched two new tools for customizing microbial analysis solutions: a first-of-its-kind Custom dPCR Microbial Assays design tool and QIAseq xHYB Custom Microbial Panels. The dPCR tool enables customized primer and probe design for bacterial, fungal, and viral targets, while the NGS panels allow comprehensive genome coverage for improved microbial detection. These additions complement QIAGEN's existing portfolio of over 700 digital PCR assays for microbial targets, accessible through the GeneGlobe platform. The new tools enhance capabilities in applications ranging from wastewater testing to food production and human pathogen analysis.

QIAGEN (NYSE: QGEN) has announced a three-year collaboration with McGill University Centre for Microbiome Research to advance microbiome sciences. The partnership will focus on DNA extraction from low microbial biomass samples and anaerobic culturing protocols, targeting the $1.8 billion North American market. McGill will serve as a beta-testing site for new QIAGEN microbiome solutions and receive reagents for research across microbiology and genomic processing workflows. The collaboration aims to generate evidence-based knowledge for medicine and public health while supporting innovation in understanding how microbial communities impact human health and ecosystems.

QIAGEN reported strong Q3 2024 results with net sales of $502 million, representing a 5% increase at actual rates and 6% at constant exchange rates (CER), exceeding the outlook of $495 million CER. The company achieved a 29.6% adjusted operating income margin, up 3 percentage points from Q3 2023. Free cash flow increased 73% to $364 million in the first nine months of 2024. Based on solid performance, QIAGEN reaffirmed its FY 2024 net sales outlook of at least $1.985 billion CER and increased its adjusted diluted EPS outlook to at least $2.19 CER from the previous $2.10 CER.

QIAGEN has received FDA clearance for its QIAstat-Dx Meningitis/Encephalitis Panel, marking its fourth FDA clearance in 2024. The panel enables rapid diagnosis of central nervous system infections, delivering results in about one hour using real-time PCR technology, compared to traditional methods requiring 24+ hours. The test simultaneously analyzes common viral, bacterial, and fungal pathogens responsible for community-acquired meningitis/encephalitis. This approval expands QIAGEN's FDA-cleared test menu, which now covers respiratory, gastrointestinal, and central nervous system infections. The system offers unique features including cycle threshold values and amplification curves for enhanced clinical information.

QIAGEN has received FDA clearance for its QIAstat-Dx Respiratory Panel Mini test, marking its third FDA clearance in 2024. The test targets five key respiratory pathogens: influenza A, influenza B, human rhinovirus, RSV, and SARS-CoV-2. It delivers results in about one hour with minimal hands-on time using real-time PCR technology. This complements the previously cleared 21-target QIAstat-Dx Respiratory Panel Plus, offering clinicians flexibility between comprehensive and targeted testing approaches. The Mini panel is specifically designed for outpatient settings, while the Plus panel suits hospitalized patients with severe disease risk factors.

QIAGEN has announced key updates to its sample technologies solutions for non-invasive liquid biopsy applications. These enhancements are designed for use in research and clinical applications such as oncology, prenatal care, and organ transplantation. The updates include:

1. An upgraded EZ1&2 ccfDNA Kit that now supports processing of 24 samples with up to 10 mL of serum or plasma, along with a new urine protocol.

2. New QIAsymphony DSP Circulating DNA Kit (96) and QIAsymphony DSP Circulating DNA Maxi Kit (192) for fully automated extraction of ccfDNA from up to 10mL sample volume.

These updates are designed to improve results when processing larger sample volumes, important for oncology research and diagnostics. The new kits are intended for in-vitro diagnostic (IVD) use, complying with CE-IVDR and FDA regulations.

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) has announced its plans to release Q3 2024 results and hold a webcast. The press release will be issued on Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. A conference call is scheduled for Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.

Participants have three options to join the conference call: register for a call back connection, dial-in by phone, or access the audio webcast. The company advises joining the event 5-10 minutes before the start time to avoid waiting. A conference call replay will be available after the event. For further information, interested parties can contact IR@qiagen.com.

QIAGEN is sponsoring the annual Global TB Summit from October 8-11, 2024, addressing the resurgence of tuberculosis as a leading infectious killer. The event will gather thousands of healthcare professionals, advocates, and policymakers from over 170 countries. Key points include:

- TB incident rate rose by 3.9% in 2022, with 10.6 million people falling ill and 1.3 million deaths
- QIAGEN's QuantiFERON-TB Gold Plus test plays a important role in detecting latent TB infection
- Over 35 top TB experts will discuss advancements in diagnostics and new treatment strategies
- The summit offers CPD and CME credits and emphasizes the need for renewed global efforts in TB control
- Topics include global and regional TB updates, challenges in special populations, and socioeconomic factors influencing TB

The event aims to foster collaboration and innovation in the fight against TB, with a focus on early detection and prevention strategies.

Neogen (NASDAQ: NEOG) has announced the appointment of Thierry Bernard as a new director to its Board, effective November 1, 2024. Bernard, the current CEO of QIAGEN N.V., brings extensive experience in science and technologies relevant to Neogen's markets. Jim Borel, Neogen's Board Chair, expressed confidence that Bernard's expertise will provide significant value during the company's continued growth.

Bernard has been CEO of QIAGEN since March 2020, after joining the company in 2015. His prior experience includes 15 years at bioMérieux SA, where he held various senior roles, including Corporate Vice President of Global Commercial Operations, Investor Relations, and the Greater China Region. This appointment aligns with Neogen's commitment to enhancing global food security.